Development, Progression, and Mortality of Suspected Interstitial Lung Disease in COPDGene
- PMID: 39133466
- PMCID: PMC11716042
- DOI: 10.1164/rccm.202402-0313OC
Development, Progression, and Mortality of Suspected Interstitial Lung Disease in COPDGene
Abstract
Rationale: Some with interstitial lung abnormalities (ILA) are suspected to have interstitial lung disease (ILD), a subgroup with adverse outcomes. Rates of development and progression of suspected ILD and their effect on mortality are unknown. Objectives: To determine rates of development, progression, and mortality in those with suspected ILD and assess effects of individual ILD and progression criteria. Methods: Participants from COPDGene (Genetic Epidemiology of Chronic Obstructive Pulmonary Disease) with ILA characterization and FVC at enrollment and 5-year follow-up were included. ILD was defined as ILA and fibrosis and/or FVC < 80% predicted. Prevalent ILD was assessed at enrollment and incident ILD and progression were assessed at 5-year follow-up. Computed tomography (CT) progression was assessed visually and FVC decline as relative change. Multivariable Cox regression tested associations between mortality and prevalent ILD, incident ILD, and progression groups. Measurements and Main Results: Of 9,588 participants at enrollment, 268 (2.8%; 51% of ILA) had prevalent ILD. Those with prevalent ILD had 51% mortality after median 10.6 years, which was higher than those with ILA without prevalent ILD (henceforth ILA) (33%; hazard ratio [HR], 2.0; P < 0.001). The subgroup of prevalent ILD with only fibrosis criteria (FVC ≥ 80%) had worse mortality (58%) than ILA (HR, 2.2; P < 0.001). A total of 98 participants with prevalent ILD completed 5-year follow-up: 33% had stable CT and relative FVC decline <10%, 6% had FVC decline ≥10% only, 39% had CT progression only, and 22% had both CT progression and FVC decline ≥10%. Mortality rates were 31%, 50%, 45%, and 45%, respectively; those with only CT progression had worse mortality than those with ILA (HR, 2.6; P = 0.005). At 5-year follow-up, incident ILD occurred in 148/4,842 participants without prevalent ILD (5.5/1,000 person-years) and had worse mortality than ILA (HR, 2.4; P < 0.001). Conclusion: Rates of mortality and progression are high among those with suspected ILD in COPDGene; fibrosis and radiologic progression are important predictors of mortality.
Keywords: ILD; idiopathic pulmonary fibrosis; interstitial lung abnormalities; pulmonary fibrosis.
Comment in
-
Big Things Have Small Beginnings: Clinical Implications of Early Interstitial Lung Disease.Am J Respir Crit Care Med. 2024 Dec 15;210(12):1394-1395. doi: 10.1164/rccm.202408-1611ED. Am J Respir Crit Care Med. 2024. PMID: 39312209 Free PMC article. No abstract available.
References
-
- Putman RK, Hatabu H, Araki T, Gudmundsson G, Gao W, Nishino M, et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators; COPDGene Investigators Association between interstitial lung abnormalities and all-cause mortality. JAMA . 2016;315:672–681. - PMC - PubMed
-
- Pompe E, de Jong PA, Lynch DA, Lessmann N, Isgum I, van Ginneken B, et al. Computed tomographic findings in subjects who died from respiratory disease in the National Lung Screening Trial. Eur Respir J . 2017;49:1601814. - PubMed
-
- Park S, Choe J, Hwang HJ, Noh HN, Jung YJ, Lee JB, et al. Long-term follow-up of interstitial lung abnormality: implication in follow-up strategy and risk thresholds. Am J Respir Crit Care Med . 2023;208:858–867. - PubMed
-
- Sanders JL, Axelsson G, Putman R, Menon A, Dupuis J, Xu H, et al. The relationship between interstitial lung abnormalities, mortality, and multimorbidity: a cohort study. Thorax . 2023;78:559–565. - PubMed
MeSH terms
Grants and funding
- R01 HL152728/HL/NHLBI NIH HHS/United States
- T32 HL007633/HL/NHLBI NIH HHS/United States
- R01 HL130974/HL/NHLBI NIH HHS/United States
- R01 HL147148/HL/NHLBI NIH HHS/United States
- U01CA209414/HL/NHLBI NIH HHS/United States
- R01 CA203636/HL/NHLBI NIH HHS/United States
- R01 HL137148/HL/NHLBI NIH HHS/United States
- R01 HL149861/HL/NHLBI NIH HHS/United States
- R01 HL133135/HL/NHLBI NIH HHS/United States
- K08 HL173562/HL/NHLBI NIH HHS/United States
- R01 HL153248/HL/NHLBI NIH HHS/United States
- U01 HL089897/HL/NHLBI NIH HHS/United States
- K08 HL140087/HL/NHLBI NIH HHS/United States
- R01 HL111024/HL/NHLBI NIH HHS/United States
- U01 HL089856/HL/NHLBI NIH HHS/United States
- R01 HL135142/HL/NHLBI NIH HHS/United States
- R01 HL170151/HL/NHLBI NIH HHS/United States
- K08 HL159318/HL/NHLBI NIH HHS/United States
- R01 HL137927/HL/NHLBI NIH HHS/United States
- R01 CA203636/CA/NCI NIH HHS/United States
- U01 CA209414/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Research Materials
